CytomX Therapeutics, Inc. (FRA:6C1)
Germany flag Germany · Delayed Price · Currency is EUR
4.876
+0.470 (10.67%)
Last updated: Jan 28, 2026, 8:02 AM CET

CytomX Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
113.63138.1101.2153.1637.3168.43
Revenue Growth (YoY)
-10.26%36.45%90.38%42.48%-45.47%154.36%
Gross Profit
113.63138.1101.2153.1637.3168.43
Selling, General & Admin
28.129.7330.0240.4539.1636.03
Research & Development
62.2883.3877.68106.55114.19112.94
Operating Expenses
90.38113.11107.7147153.35148.97
Operating Income
23.2525-6.48-93.84-116.04-80.54
Interest & Investment Income
57.149.841.680.261.84
Currency Exchange Gain (Loss)
0.01-0.04-0.030.34-0.08-0.03
EBT Excluding Unusual Items
28.2632.093.32-91.82-115.87-78.73
Merger & Restructuring Charges
----7.5--
Pretax Income
28.2632.093.32-99.32-115.87-78.73
Income Tax Expense
0.250.223.89---13.91
Net Income
28.0231.87-0.57-99.32-115.87-64.82
Net Income to Common
28.0231.87-0.57-99.32-115.87-64.82
Shares Outstanding (Basic)
1178474666446
Shares Outstanding (Diluted)
1188574666446
Shares Change (YoY)
41.04%14.82%12.27%2.48%39.01%1.79%
EPS (Basic)
0.240.38-0.01-1.51-1.81-1.40
EPS (Diluted)
0.240.38-0.01-1.51-1.81-1.40
Free Cash Flow
-72.35-86.54-56.88-112.53-120.642.95
Free Cash Flow Per Share
-0.61-1.02-0.77-1.71-1.880.06
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
20.46%18.10%-6.41%-176.50%-311.00%-117.70%
Profit Margin
24.66%23.08%-0.56%-186.82%-310.54%-94.73%
Free Cash Flow Margin
-63.67%-62.66%-56.19%-211.67%-323.33%4.31%
EBITDA
24.5326.76-4.31-91.39-113.34-77.97
EBITDA Margin
21.58%19.38%-4.26%-171.91%--113.94%
D&A For EBITDA
1.281.772.182.442.712.57
EBIT
23.2525-6.48-93.84-116.04-80.54
EBIT Margin
20.46%18.10%-6.41%-176.50%--117.70%
Effective Tax Rate
0.87%0.70%117.12%---
Source: S&P Global Market Intelligence. Standard template. Financial Sources.